Model-Based Meta-Analysis for All Phases of Drug Development: Capturing the Full Potential of Published Clinical Trial Outcomes [APAC Webinar]

Model-based meta-analysis (MBMA) is a valuable tool that leverages published clinical outcome data to address critical drug development questions. Applications of MBMA can range from, for example, understanding the competitive landscape and the likelihood of a new drug’s success to benchmarking a new drug’s performance with a synthetic control arm to leveraging covariate relationships from competitors to design better trials. With access to relevant, publicly-available clinical study via the CODEX Clinical Outcome Databases, you can quickly understand what safety and efficacy targets are necessary for differentiation, optimize trial design, and improve the accuracy of early-phase and go/no-go decisions.

In this educational webinar, our experts will address common questions such as; When and how can CODEX and MBMA be integrated into your workflow? Is MBMA useful in the early stages of development in addition to later stages? What if your team lacks MBMA specialists? How to use early endpoints/biomarkers to predict late endpoints?

We’ll explore MBMA’s applications across all phases of drug development, showing how you can utilize this tool to its fullest potential at any stage.